-Reuters
JP Morgan Downgrades Global Blood Therapeutics to Neutral, Announces $36 Price Target
JP Morgan analyst Tessa Romero downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and announces $36 price target.
Related Posts
SiteOne Landscape Supply Q2 Sales $1.22B Miss $1.24B Estimate
SiteOne Landscape Supply (NYSE:SITE) reported quarterly sales of $1.22 billion which missed the analyst consensus estimate of $1.24 billion by 1.61 percent. This is a 12.55 percent increase over sales of $1.08 billion
Shiba Inu Surges 3% After Shibarium Portal Launch, Shytoshi Kusama’s ‘Important’ Reminder
Shiba Inu (CRYPTO: SHIB) is up 3.12% in the last 24 hours, after Shytoshi Kusama, the lead developer of SHIB, released a new network adoption portal, 'Join Shibarium', on Sunday.
